Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
The most-watched drug in the weight-management pipeline — and it is not yet an approved medication. Here's what's actually known.
Retatrutide gets discussed online as if it's already available. It isn't. This page separates the real trial data from the hype, and explains why Bioaminex won't offer it until it clears FDA review.
Retatrutide is Eli Lilly's investigational "triple agonist" — the first peptide in this drug class to reach Phase 3 trials by activating three hormone receptors at once (GLP-1, GIP, and glucagon) rather than one or two. It is not approved by any regulatory agency anywhere in the world. Anyone selling it as a finished product outside of a clinical trial is selling an unapproved, unregulated compound with no manufacturing oversight.
Adding glucagon-receptor activity to the GLP-1/GIP combination (the same dual mechanism tirzepatide uses) is thought to add an energy-expenditure effect on top of appetite suppression and improved insulin signaling — a mechanism aimed at outperforming existing GLP-1 and dual-agonist drugs.
The pivotal Phase 3 TRIUMPH-1 obesity trial reported an average 28.3% body-weight reduction at 80 weeks on the highest studied dose, with results holding up in longer extensions. A companion trial, TRIUMPH-4, showed comparable results in participants with obesity and knee osteoarthritis. These numbers are notable — higher than currently approved GLP-1 drugs have shown in trials — but they come from a controlled trial setting, on a formulation and dosing schedule that isn't yet finalized for market. Lilly has indicated it's on track to file for FDA approval in late 2026, which — if the typical review timeline holds — points to possible approval in 2027 at the earliest.
Reported side effects mirror other incretin drugs — nausea, diarrhea, and other GI effects — but the full safety profile isn't established the way it is for an approved drug with years of post-market data. That's precisely the gap a trial exists to close, and precisely why a compound at this stage doesn't belong in a compounding pharmacy or a gray-market vial.
Retatrutide's early trial results are genuinely impressive, and it's reasonable to be excited about where the science is headed. But "impressive Phase 3 data" and "available medication" are different things. Until it's approved, the only responsible way to access it is through a clinical trial — not a website, and not us.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense retatrutide or any medication.